The MRC/ABPI COPD Cohort v1.7 (COPDMAP)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01620645|
Recruitment Status : Unknown
Verified June 2012 by University College, London.
Recruitment status was: Recruiting
First Posted : June 15, 2012
Last Update Posted : June 15, 2012
|Condition or disease||Intervention/treatment|
|COPD||Radiation: CT scan and PA chest X-ray|
|Study Type :||Observational|
|Estimated Enrollment :||400 participants|
|Official Title:||The Mechanisms of Inflammation and Immunity in COPD and Their Relationship to Exacerbations and Disease Progression.|
|Study Start Date :||February 2011|
|COPD, GOLD II severity or above||
Radiation: CT scan and PA chest X-ray
All participants will receive a single high resolution CT scan of the chest. This will be performed using a low tube current, helical technique. Participants may also receive a plain chest X-ray if clinically indicated.
The total research protocol dose is 2 mSv. The dose from the chest X-ray is insignificant compared with the dose from the CT scan of the chest, therefore all this dose can be considered to be additional to standard of care. A dose of 2 mSv represents a risk of radiation induced detriment of approximately 1 in 10,000 and is equivalent to about 11 months of average natural background radiation in the UK.
Blood, sputum and urine samples will be collected. Commercially available ELISA assays will be be used to qualify inflammatory markers.
Quantitative bacterial culture will be performed on sputum samples. Bacterial and viral load will be determined by polymerase chain reaction (PCR). Proteomics such as Cholesterol, BNP, CRP by routine hospital assay techniques. Specific DNA sections will be selected from the genome to identify/confirm genes believed to be associated with different COPD phenotypes by molecular techniques.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01620645
|Royal Free Hampstead NHS Trust||Recruiting|
|London, United Kingdom, NW3 2QG|
|Contact: Richa Singh, MA MBBS MRCP +442077940500 ext 34308 email@example.com|
|Contact: Gavin Donaldson, BSc PhD +442077940500 ext 34308 firstname.lastname@example.org|
|Principal Investigator: Wisia Wedzicha, BSc MBBS MD|